机构：[1]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[2]Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[3]Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, Changsha, China[4]Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[5]Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China浙江省肿瘤医院[6]Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China[7]Department of Breast Cancer, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China[8]Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属协和医院[9]Department of Breast Oncology, Key Laboratory of Breast Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China[10]Department of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China[11]Department of Medical Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China江苏省人民医院[12]Department of Breast Surgery, Sichuan Province Tumor Hospital, Chengdu, China外科中心乳腺外科中心四川省肿瘤医院乳腺科[13]Department of Medical Oncology, Yunnan Cancer Hospital, Kunming Medical University, Kunming, China[14]Department of Breast Surgery, The Affiliated Tumor Hospital of Guangxi Medical University, Guangxi, China[15]Department of Medical Oncology and Thoracic Surgery, The First Hospital of China Medical University, Shenyang, China[16]Department of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Key Laboratory of Liaoning Breast Cancer Research, Shenyang, China[17]The 4th Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China[18]Department of the Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, China重庆医科大学附属第一医院[19]Department of Medicine Oncology, 900 Hospital of the Joint Logistics Team, Fuzhou, China[20]Department of Breast Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China[21]Department of Oncology, General Hospital of Ningxia Medical University, Ningxia, China[22]Department of Breast Cancer and Lymphoma, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China
Background Clinical guidelines generally recommend endocrine therapy (ET) as first-line treatment of hormone receptor-positive advanced breast cancer (HR+ ABC) whereas chemotherapy (CT) should be considered in the presence of life-threatening disease or limited clinical benefit after three sequential ET regimens. However, it is unclear if real-world clinical practice is in accordance with the current guidelines. This study was to present the real-world treatment patterns and ET regimens among HR+ ABC patients in China. Methods Using data from the Nation-wide Multicenter Retrospective Clinical Epidemiology Study of Female Advanced Breast Cancer in China (ClinicalTrials.gov identifier: NCT03047889), we investigated the clinicopathological characteristics, clinical profiles, and treatment patterns of HR+ ABC patients from January 2012 to December 2014. Results A total of 2,342 patients with HR+ ABC were included in this study. Our findings revealed that, in comparisons with those receiving initial CT (n = 1445), patients initiated ET (n =402) were significantly older, later recurrent after adjuvant treatment, with a lower rate of visceral involvement and a decreasing quantity of metastatic sites. A total of 1,308 patients received palliative ET while only 18.9% patients (n = 247) reached three lines of ET. Among patients completing more than one line of ET, the median treatment duration was 8 months for the first line, 6 months for the second line, and 3 months for the third line for patients receiving ET. In the advanced setting, the choices of palliative ET regimens were diverse, yet aromatase inhibitor (AI) monotherapy was still the overall mainstay of ET; in contrast, patients were less accessible to everolimus plus AI regimen in this population. Conclusions Less than one quarter of patients initiated palliative ET for HR+ ABC in routine clinical practice. Patients who received multi-lines of ET experienced successive shorter durations following each line of therapy. This real-life data provides a solid overview of ET for HR+ ABC from China, indicating unmet need for treatment options that improve the effectiveness of endocrine therapy.
基金：
Investigator-initiated program of the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital; Chinese Academy of Medical Sciences; Peking Union Medical College [CH-BC-045]
第一作者机构：[1]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
通讯作者：
推荐引用方式(GB/T 7714)：
Yun Wu,Yiqun Han,Pei Yu,et al.Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China[J].FRONTIERS IN ONCOLOGY.2021,10:doi:10.3389/fonc.2020.599604.
APA：
Yun Wu,Yiqun Han,Pei Yu,Quchang Ouyang,Min Yan...&Binghe Xu.(2021).Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China.FRONTIERS IN ONCOLOGY,10,
MLA：
Yun Wu,et al."Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China".FRONTIERS IN ONCOLOGY 10.(2021)
